Tuesday’s business headlines
INDIANAPOLIS (WISH) — Here’s a look at Tuesday’s business headlines with Jane King.
Lilly reveals drug prices
Pharmaceutical giant Eli Lilly pulled the curtain back on the confidential pricing structure for one of its blockbuster drugs.
The “net price” patients actually pay for Eli Lilly’s insulin fell by 8.1 percent to $135 a patient per month in 2018 from $147 in 2014.
The net price is the total paid after factoring in rebates and discounts.
High drug costs have become a rare bipartisan issue with lawmakers on both sides of the aisle demanding something be done.
Muscular dystrophy drug
Researchers in Florida never expected this much success with a drug they’re developing to treat muscular dystrophy.
The potential drug improved muscle defects with no apparent side effects in tests using mice, the Scripps researchers say.
The results were better than expected. Human trials still have to be conducted.
$11 million donation
The parent company of Krispy Kreme, Panera Bread, Keurig and Dr. Pepper admits to a family history with Nazi ties.
The Reimann family, which owns the controlling stake in JAB Holdings and is reportedly one of the richest families in Germany, will donate $11 million to an undisclosed charity because of the family ties to Nazism in World War II.
Personalized drive-thru experience
McDonald’s is buying a tech company to personalize its drive-thru experience.
Dynamic Yield is the name of the company and it’s digital drive-thru menus change based on different factors, such as the weather and current restaurant traffic.
It will begin rolling out to U.S. restaurants this year.
Physical books vs. e-books
Research finds parents engage less with the toddlers when reading e-books versus print books.
The University of Michigan C.S. Mott Children’s Hospital watched 37 parent-toddler pairs page through print books, basic electronic books on a tablet, as well as enhanced e-books on tablets that featured animation and sound effects.
It found when parents and kids spoke they were more likely to talk about the device rather than the story.